Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.pulmoe.2020.07.003 http://scihub22266oqcxt.onion/10.1016/j.pulmoe.2020.07.003 32713784!7369580!32713784     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pulmonology 2021 ; 27 (1): 52-66 Nephropedia Template TP {{tp|p=32713784|t=2021. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review |pdf=|usr=}}{{32713784}} gab.com Text Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review JO: Pulmonology http://www.kidney.de/pget.php?&tw=1&pmid=32713784 #FOAvip BACKGROUND: Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety. METHODS: MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis until 20th June 2020. RESULTS: We identified 3 indirect pre-clinical studies and 28 clinical studies including 5776 patients with COVID-19 (13 with a comparison group, 15 single-arm). To date, no randomized trials have been published. We retrieved no studies at low risk of bias. Forty-five ongoing studies were retrieved from trial registries. CONCLUSIONS: There is insufficient evidence regarding the clinical efficacy and safety of tocilizumab in patients with COVID-19. Its use should be considered experimental, requiring ethical approval and clinical trial oversight. Twit Text FOAVip Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review ????Pulmonology http://www.kidney.de/pget.php?&tw=1&pmid=32713784 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32713784 #FOAvip English Wikipedia <ref>{{Cite pmid|32713784}}</ref> Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review #MMPMID32713784 Cortegiani A; Ippolito M; Greco M; Granone V; Protti A; Gregoretti C; Giarratano A; Einav S; Cecconi M Pulmonology 2021[Jan]; 27 (1): 52-66 PMID32713784show ga BACKGROUND: Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety. METHODS: MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis until 20th June 2020. RESULTS: We identified 3 indirect pre-clinical studies and 28 clinical studies including 5776 patients with COVID-19 (13 with a comparison group, 15 single-arm). To date, no randomized trials have been published. We retrieved no studies at low risk of bias. Forty-five ongoing studies were retrieved from trial registries. CONCLUSIONS: There is insufficient evidence regarding the clinical efficacy and safety of tocilizumab in patients with COVID-19. Its use should be considered experimental, requiring ethical approval and clinical trial oversight. |*COVID-19 Drug Treatment[MESH] |Animals[MESH] |Antibodies, Monoclonal, Humanized/pharmacology/*therapeutic use[MESH] |Humans[MESH] |Interleukin-6/antagonists & inhibitors[MESH]Rationale and evidence on the use of tocilizumab in COVID-19: a system(epmc).pdf DeepDyve Pubget Overpricing